# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Audre Lorde (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML016-SYN
- Date: 2026-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Naomi Fairweather, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for primary care survivorship visit five and a half months after right mastectomy for stage IA breast cancer, on tamoxifen. **S**

## Objective

PHQ-9: 4; GAD-7: 3. All results are synthetic.

BP 124/78 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 72 kg; BMI 25.5 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Invasive ductal carcinoma of the upper outer quadrant of the right breast, stage IA (pT1c pN0(sn) M0), grade 2, estrogen and progesterone receptor positive, HER2 negative, recurrence score 14; treated by right total mastectomy with sentinel node biopsy and on adjuvant tamoxifen; synthetic modern counterpart of the documented 1978 breast cancer and mastectomy; Estrogen receptor positive status of the breast cancer (ER 90 percent, PR 60 percent); Absence of the right breast after mastectomy with flat closure; she chose not to have reconstruction and not to wear an external prosthesis; Long-term use of tamoxifen as adjuvant endocrine therapy. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five years **S**

## Plan

- Medical oncology consultation to confirm the adjuvant endocrine therapy plan, advise on hot flashes, set the surveillance plan, and advise on genetic assessment. Guideline: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019) **S**
- Tamoxifen 20 mg daily for at least five years, with questions at every visit about hot flashes, abnormal vaginal bleeding, and leg swelling or breathlessness, and a yearly gynecologic assessment. Guideline: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Lymphedema risk counseling and arm checks at every visit; bone health by calcium and vitamin D from diet and weight-bearing exercise; distress, depression, and anxiety screening at intervals. Guideline: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Written survivorship care plan, at least 150 minutes of activity a week, alcohol at or below one drink a day, and her decisions about reconstruction and a prosthesis recorded and respected. Guideline: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
